Sun Pharma Submits Binding USD 13 Billion Bid for Organon, Deal May Be India's Largest Pharma Acquisition: Report

The proposed acquisition reflects the company’s ambition to move beyond its strong generics base and expand into higher-value branded and specialty segments, significantly enhancing its global presence and diversified portfolio.

As per a recent media report in The Economic Times, Sun Pharma is competing with other bidders, including private equity firm EQT and German drugmaker Gruenthal, making the transaction highly competitive.

The deal is expected to be fully financed through a combination of debt arranged by global banks and internal cash reserves. As part of the acquisition, Sun Pharma may also take on Organon’s existing debt, estimated to be between $8 billion and $9 billion.

Organon is viewed as an attractive acquisition target due to its established portfolio in women’s health, including treatments related to contraception, menopause, osteoporosis, and breast cancer, along with a growing biosimilars business that offers long-term growth potential.

However, the potential deal carries financial and operational risks, with analysts raising concerns over the high debt burden, possible integration challenges, and pressure on Sun Pharma’s balance sheet post-acquisition.

Market sentiment has reflected caution, with Sun Pharma’s shares witnessing a decline following reports of the bid, while Organon’s stock has shown fluctuations amid takeover developments, reports The Economic Times.

If finalised, the acquisition could mark a defining moment for India’s pharmaceutical sector, elevating Sun Pharma’s global standing and reshaping its long-term growth strategy.